bluebird bio to be Acquired by Carlyle and SK Capital Partners

bluebird bio, Inc. has agreed to be acquired by Carlyle and SK Capital Partners, LP in collaboration with a team of experienced biotech executives. Carlyle and SK Capital aim to provide primary capital to scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.

Under the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, potentially totaling up to $9.84 per share in cash, subject to certain conditions. The acquisition is seen as vital for the long-term future of bluebird's therapies.

David Meek, the former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. The transaction is expected to close in the first half of 2025, making bluebird a privately held company. Following the acquisition, bluebird's common stock will no longer be listed on any public market.

Source: BusinessWire